This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

SYNLAB Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

SYNLAB hat ein Gesamteigenkapital von €2.4B und eine Gesamtverschuldung von €924.8M, wodurch sich der Verschuldungsgrad auf 39% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen €4.7B bzw. €2.3B. SYNLAB Das EBIT des Unternehmens beträgt €151.2M, so dass der Zinsdeckungsgrad 1.8 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von €300.5M.

Wichtige Informationen

39.0%

Verhältnis von Schulden zu Eigenkapital

€924.83m

Verschuldung

Zinsdeckungsgrad	1.8x
Bargeld	€300.47m
Eigenkapital	€2.37b
Gesamtverbindlichkeiten	€2.34b
Gesamtvermögen	€4.71b

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger

Dec 15

Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)

Sep 10

SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 14

SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market

May 29

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: SYABDie kurzfristigen Aktiva des Unternehmens (€860.3M) übersteigen seine kurzfristigen Passiva (€693.9M).

Langfristige Verbindlichkeiten: SYABDie kurzfristigen Vermögenswerte des Unternehmens (€860.3M) decken seine langfristigen Verbindlichkeiten (€1.6B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: SYABDie Nettoverschuldung im Verhältnis zum Eigenkapital (26.3%) wird als zufriedenstellend angesehen.

Schulden abbauen: SYAB Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 248.8% auf 39% zurückgegangen.

Schuldendeckung: SYABDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (45.3%).

Zinsdeckung: SYABDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (1.8x Deckung) nicht gut gedeckt.

This company listing is no longer active

SYNLAB Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

SYNLAB AG(XTRA:SYAB) dropped from Germany SDAX (Total Return) Index

First quarter 2024 earnings released: EPS: €0.11 (vs €0.13 in 1Q 2023)

SYNLAB AG Provides Earnings Guidance for the Year 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 9.8% to €11.93

SYNLAB AG to Report Q3, 2024 Results on Nov 07, 2024

Third quarter 2023 earnings released: EPS: €0.59 (vs €0.31 in 3Q 2022)

Synlab Launches Revolutionary Bipolar Disorder Diagnostic Test

SYNLAB AG to Report Fiscal Year 2023 Results on Mar 25, 2024

Investor sentiment improves as stock rises 17%

Price target increased by 8.2% to €11.44

New major risk - Financial position

Second quarter 2023 earnings released: EPS: €0.053 (vs €0.42 loss in 2Q 2022)

SYNLAB AG Provides Significant Support for the Largest Ever Multi-National Study on Cholesterol

Upcoming dividend of €0.33 per share at 3.3% yield

Consensus EPS estimates fall by 14%

Full year 2022 earnings: Revenues in line with analyst expectations

Consensus EPS estimates fall by 26%

Investor sentiment improves as stock rises 31%

Consensus EPS estimates fall by 18%

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 11% to €15.62

Price target decreased to €16.84

SYNLAB AG, Annual General Meeting, May 17, 2023

Price target decreased to €17.08

Investor sentiment deteriorated over the past week

SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger

Price target decreased to €17.51

Price target decreased to €18.26

Price target decreased to €18.96

SYNLAB AG (DB:SYAB) announces an Equity Buyback for 1,860,647 shares, for €31.63 million.

Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Second quarter 2022 earnings released

Consensus EPS estimates increase by 14%

SYNLAB AG Revises Earnings Guidance for the Fiscal Year 2022

SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

SYNLAB (FRA:SYAB) Is Investing Its Capital With Increasing Efficiency

Investor sentiment improved over the past week

SYNLAB AG Revises Earnings Guidance for 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

SYNLAB AG (DB:SYAB) acquired Sistemas Genomicos S.L. from Ascires Biomedical Group.

Are Investors Undervaluing SYNLAB AG (FRA:SYAB) By 25%?

Shareholders Will Be Pleased With The Quality of SYNLAB's (FRA:SYAB) Earnings

SYNLAB AG (DB:SYAB) agreed to acquire Laboratorio Médico Polanco and Laboratorio Clinicos de Puebla from Médica Sur, S.A.B. de C.V. (BMV:MEDICA B).

SYNLAB AG Provides Screenings for Pupils in North Rhine-Westphalia with the So-Called Lollipop-PCR-Tests

Synlab Introduces New PCR Pooling Test Method for Companies

SYNLAB AG has completed an IPO in the amount of €1.11875 billion.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen